Systematic review shows increased risk for exacerbations and worsening asthma control after omalizumab discontinuation.
This review indicates that, although most patients maintain stable objective indicators after omalizumab discontinuation, a significant proportion are at increased risk for exacerbations, deterioration in asthma control, and increased corticosteroid use, particularly within the first year.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: